PMV Pharmaceuticals, Inc. financial data

Symbol
PMVP on Nasdaq
Industry
Pharmaceutical Preparations
Location
One Research Way, Princeton, NJ
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 7, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.6K % -20.2%
Debt-to-equity 11.7 % +13.6%
Return On Equity -24.2 % +22.3%
Return On Assets -21.7 % +23.3%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 51.7M shares +1.15%
Common Stock, Shares, Outstanding 51.7M shares +1.16%
Entity Public Float 209M USD -61.5%
Weighted Average Number of Shares Outstanding, Basic 51.6M shares +5.15%
Weighted Average Number of Shares Outstanding, Diluted 51.6M shares +5.15%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 58.1M USD +1.07%
General and Administrative Expense 21M USD -15.4%
Operating Income (Loss) -79.2M USD +3.9%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -67.6M USD +6.86%
Income Tax Expense (Benefit) 74K USD
Net Income (Loss) Attributable to Parent -51.5M USD +29.1%
Earnings Per Share, Basic -0.99 USD/shares +36.5%
Earnings Per Share, Diluted -0.99 USD/shares +36.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 48.8M USD -6.24%
Marketable Securities, Current 134M USD -10.6%
Cash, Cash Equivalents, and Short-term Investments 198M USD -16.9%
Assets, Current 190M USD -7.64%
Property, Plant and Equipment, Net 10.1M USD -6.39%
Operating Lease, Right-of-Use Asset 8.41M USD -1.62%
Other Assets, Noncurrent 242K USD +34.4%
Assets 223M USD -14.4%
Accounts Payable, Current 2.06M USD +22.9%
Accrued Liabilities, Current 10.3M USD +13.5%
Liabilities, Current 13.6M USD +26.6%
Operating Lease, Liability, Noncurrent 12M USD -5.32%
Liabilities 25.6M USD +9.28%
Accumulated Other Comprehensive Income (Loss), Net of Tax 410K USD
Retained Earnings (Accumulated Deficit) -346M USD -17.5%
Stockholders' Equity Attributable to Parent 198M USD -16.7%
Liabilities and Equity 223M USD -14.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -16.2M USD -7.81%
Net Cash Provided by (Used in) Financing Activities 12K USD -90.6%
Net Cash Provided by (Used in) Investing Activities 26.2M USD -47.3%
Common Stock, Shares Authorized 1B shares 0%
Common Stock, Shares, Issued 51.7M shares +1.16%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9.95M USD -71.3%
Deferred Tax Assets, Valuation Allowance 93.8M USD +25.2%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0 pure
Deferred Tax Assets, Gross 96.4M USD +24.1%
Operating Lease, Liability 13.3M USD +4.47%
Depreciation 1.46M USD +50.5%
Payments to Acquire Property, Plant, and Equipment 594K USD +281%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -50.7M USD +29.5%
Property, Plant and Equipment, Gross 14.2M USD +3.23%
Operating Lease, Liability, Current 1.24M USD
Operating Lease, Weighted Average Discount Rate, Percent 0.06 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 3.23M USD -13.9%
Deferred Tax Assets, Operating Loss Carryforwards 56.7M USD +14.7%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 3.17M USD +30.2%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 2.58M USD -5.92%
Share-based Payment Arrangement, Expense 10.6M USD -15.2%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%